| MRSH |
Report |
Total Revenue (Q2 2026) |
BEAT |
pred ~$7.35B vs. cons $7.276B |
MEDIUM |
| MRSH |
Report |
Adjusted EPS (Q2 2026) |
BEAT |
pred ~$2.95 vs. cons $2.888 |
MEDIUM |
| MRSH |
Report |
Organic Revenue Growth (Q2 2026) |
BEAT |
pred ~4.0% vs. cons 3.56% |
MEDIUM |
| MRSH |
Guide |
Underlying Revenue Growth (FY 2026) |
BETTER |
guide ~4% vs. cons 3.66% |
HIGH |
| MRSH |
Guide |
Adj Operating Margin (FY 2026) |
UNCHANGED |
reiterate H2-weighted expansion vs. cons 27.15% |
HIGH |
| MRSH |
Guide |
Adj EPS Growth (FY 2026) |
UNCHANGED |
reiterate solid growth vs. cons $10.37 |
HIGH |
| MRSH |
Guide |
Fiduciary Interest Income (Q3 2026) |
UNKNOWN |
guide ~$75-78M vs. UNVERIFIED |
LOW |
| MRSH |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.5% |
— |
MEDIUM |
| MRSH |
Return |
5-day cumulative residual |
+2.0% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — sell-side confirms no implicit H2 cut; modest upward EPS revisions expected |
MEDIUM |